The Food and Drug Administration (FDA) approved Opdivo (nivolumab) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy, according to Bristol Meyers Squibb – the agent’s manufacturer.
FDA Approves Opdivo to Treat Advanced Esophageal Squamous Cell Carcinoma